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Abstract
Background: Current pre-operative staging methods for gallbladder cancer (GBC) are suboptimal in
detecting metastatic disease. Positron emission tomography (PET) may have a role but data are lacking.
Methods: Patients with GBC and PET assessed by a hepatobiliary surgeon in clinic between January
2001 and June 2013 were retrospectively reviewed. Computed tomography (CT)/magnetic resonace
imaging (MRI) were correlated with PET scans and analysed for evidence of metastatic or locally
unresectable disease. Medical records were reviewed to determine if PET scanning was helpful by
preventing non-therapeutic surgery or enabling resection in patients initially deemed unresectable.
Results: There were 100 patients including 63 incidental GBC. Thirty-eight patients did not proceed to
surgery, 35 were resected and 27 patients were explored but had unresectable disease. PET was positive
for metastatic disease in 39 patients (sensitivity 56%, specificity 94%). Five patients definitively benefitted
from PET: in 3 patients PET found disease not seen on CT, and 2 patients with suspicious CT findings had
negative PET and successful resections. In a further 12 patients PET confirmed equivocal CT findings.
Three patients had additional invasive procedures performed owing to PET avidity in other sites. Utility of
PET was higher in patients with suspicious nodal disease on CT [odds ratio (OR) 7.1 versus no nodal
disease, P = 0.0004], and in patients without a prior cholecystectomy (OR 3.1 versus post-
cholecystectomy, P = 0.04).
Conclusion: Addition of PET to conventional cross-sectional imaging has a modest impact on man-
agement pre-operatively particularly in patients without a prior cholecystectomy and to confirm suspi-
cious nodal disease on CT.
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Introduction
Gallbladder cancer (GBC) is the fifth most common gastrointes-
tinal cancer in the United States with an estimated incidence of 1.2
per 100 000 persons per year.1 Most patients have advanced or
unresectable disease at diagnosis.2,3 Early stage cancer is often
incidentally diagnosed after a cholecystectomy for presumed
benign disease.4 GBCs have a tendency to metastasize early and
widely, spreading via lymphatics, hematogenously and
intraperitoneally.5 While the overall prognosis is poor,2 a good
outcome after a complete resection is possible for early disease
(T1/T2, N0).6,7 The role of surgery for locally advanced disease
(T3/T4) and regional nodal disease (N1) is more controversial,
but surgery remains the only chance for long-term survival for
these patients.3,4,7–10 Distant metastatic disease and nodal disease
beyond the hepatoduodenal ligament (N2) are generally consid-
ered contraindications to surgery because of poor survival out-
comes after resection.
Pre-operative staging is important to identify patients with
locally advanced or metastatic disease in whom surgery is ineffec-
tive. Unfortunately, it is still common for a surgeon to embark on
surgery only to find small liver metastases, peritoneal disease, orThis study has not been previously presented at any societies or meetings.
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distant nodal disease not seen on pre-operative imaging. Current
staging tools include ultrasound, computed tomography (CT),
magnetic resonance imaging (MRI), 18F-FDG-PET (18-
fluorodeoxyglucose positron emission tomography) and laparos-
copy. In recent years, PET has been used in staging a number of
malignancies such as colorectal metastases, oesophageal cancer,
lymphoma and melanoma. It is particularly useful for detecting
occult metastatic disease and to further characterize equivocal
lesions seen on CT or MRI.
There is relatively sparse data in the literature pertaining to the
use of PET in GBC.Most published series of utility of PET in GBC
have a small number of patients, often combined with
cholangiocarcinoma.11–17 Our group previously published a series
of patients who had PET for biliary tract malignancies between
March 2001 and October 2003, including 41 gallbladder cancers.
Thirty-one of those patients had PET as part of their workup
prior to intended surgery. The sensitivity for the primary tumour
was 86% and for detecting metastatic disease 87%. For detecting
recurrence, the sensitivity and specificity were 89% and 100%,
respectively. Overall PET changed management in 7 out of 31
(23%) patients.18
In this study, we sought to determine if the utility of PET in
GBC has changed given continual improvement in multimodality
cross-sectional imaging. Specifically data were analysed for any
additional metastatic disease noted on PET that was not seen on
CT or MRI that would change surgical management, or PET
findings that help confirm equivocal lesions on conventional
imaging.
Patients and methods
The Institutional Review Board at Memorial Sloan Kettering
Cancer Center (MSKCC) granted a waiver of consent for this
retrospective study. Patients with a clinical or pathological diag-
nosis of gallbladder cancer and who had underwent PET between
January 2001 and June 2013 were identified from the institutional
administrative database at MSKCC, supplemented by patients
from departmental databases. A total of 146 patients were identi-
fied and their electronic medical records were reviewed. Eleven
patients were excluded because three had PET for reasons other
than GBC, and eight patients did not have CT or MRI to correlate
PET findings. Of the remaining 135 patients, 100 had been
assessed by a hepatobiliary surgeon and considered for surgery,
and 35 had PET for follow-up. The 100 patients who had pre-
operative PET comprised our study population. Twenty-seven
patients in this study had been included in a previously published
analysis.18
The majority of patients were referred from another institution
after a cholecystectomy for presumed benign disease but were
incidentally found to have GBC on pathological evaluation. His-
tological slides were obtained for these patients and reviewed by
pathologists at MSKCC to confirm the diagnosis of GBC. Eighty-
two patients had cross-sectional imaging performed or repeated at
MSKCC, and 12 were done at an outside institution. The scans
were performed clinically per standard institutional protocol.
Ninety-four out of 100 PET scans were performed atMSKCC. The
technique of 18F-FDG-PET at our institution has been previously
described.18 Briefly, patients were fasted for 6 h then injected with
10–15 mCi of 18F-FDG. Standardized uptake values (SUV) were
calculated and a cutoff of greater than two was considered abnor-
mal. Abnormal PET avidity was noted in the primary site (gall-
bladder or gallbladder resection bed), lymph nodes (regional or
distant) and distant sites. Eighty-seven PET scans were performed
as part of a PET-CT using a low-dose CT protocol for attenuation
correction and anatomical localization.
Demographic, clinical and pathological data, as well as treat-
ment and follow-up details were obtained from electronic
medical records. Cancer classification and staging were based on
the 7th edition of AJCC Staging Manual and wherever possible
pathological T classifications were reported. For patients without
pathological confirmation, accurate clinical T classifications were
inherently difficult; however, evidence of gross invasion of the
liver on imaging was taken as evidence of T3 disease. For scans
done at MSKCC, radiology images and reports for cross-
sectional imaging (CT or MRI) and PET were reviewed for evi-
dence of unresectable disease. For scans done at referring
institutions, data were collected from reports. Resectability was
determined on a case-by-case basis but contraindications to
resection included distant metastases, discontiguous liver metas-
tases, nodal metastases beyond the hepatoduodenal ligament and
unresectable T4 disease that invaded major vascular structures
or multiple organs. CT/MRI and PET results were classified as
positive, suspicious, or negative. The utility of PET was defined
by whether PET provided additional information to conven-
tional imaging that influenced management. PET was considered
helpful if it avoided a non-therapeutic operation, or it lead to
exploration and successful resection in patients deemed
unresectable by CT/MRI. In cases where PET lead to unneces-
sary procedures, the negative impact of PET was reported sepa-
rately. Disease resectability was confirmed at surgery, and
unexplored metastatic disease was confirmed by progression on
follow-up imaging or biopsy.
The sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) for PET to detect metastatic
disease were calculated for metastases to any site, and to the peri-
toneum, lymph nodes, liver and lung. Whenever possible, patho-
logical confirmation of metastatic disease by resection or biopsy
was used.When no pathological material was available, metastatic
disease was determined by follow-up imaging. True positives
included patients with disease confirmed by surgical exploration
or by follow-up imaging showing disease progression. True nega-
tives were confirmed by surgical exploration, or if follow-up
imaging showed no evidence of metastatic disease at that site. All
PET false positives were confirmed histologically by surgical exci-
sion or biopsies. False negatives were confirmed by surgical explo-
ration, or in correlation with CT/MRI done concurrently or
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within 1 month of PET, showing metastatic disease which subse-
quently progressed on follow-up imaging.
Statistical analyses were performed using Prism (version 6.0;
GraphPad Software, Inc., La Jolla, CA, USA). Fisher’s exact tests
were performed on categorical data; P-values of <0.05 were con-
sidered significant.
Results
One hundred patients were analysed. The median age was 67
years, with a slight female predominance. Sixty-three patients had
incidental gallbladder cancer detected after a cholecystectomy,
whereas 37 had no prior cholecystectomy. The majority of
patients (64%) had T3 disease.
Thirty-eight patients did not proceed to surgical exploration
owing to a pre-operative finding of unresectable disease. Of those
who proceeded to surgery, 35/62 (56%) were able to be resected.
Among the 27 patients deemed unresectable at surgery, peritoneal
disease was found in 13, distant nodal disease in 9, liver metastases
in 8 and locally advanced disease in 7. The patient, disease and
treatment factors are summarized in Table 1.
Table 2 shows the yield of PET for detecting unresectable
disease by T classification. The overall yield was 39/100 patients.
The yield was comparable among T2, T3 and T4 disease, but there
was an increasing trend from T1 to T4 (0%, 37%, 42% and 45%,
respectively). No patient with T1 disease had a positive PET for
unresectable disease. The yield for patients without a prior chol-
ecystectomy was 47%, compared with 34% for patients with a
prior cholecystectomy (incidental GBC), however this difference
did not reach statistical significance (P = 0.29).
Fig. 1 summarizes the utility of PET. In 73 patients CT and PET
were completely concordant and PET did not add any informa-
tion. In 27 patients, CT and PET results were disconcordant. In 3
patients, PET found metastatic disease not suspected on CT (liver,
lung, mediastinal nodes in one patient each). In 12 patients, CT
were suspicious for unresectable disease, including distant nodal
metastases in 11 and locally advanced T4 disease in one patient. In
the absence of PET, these patients may have undergone an
exploratory laparotomy and been unresectable. Hence PET con-
tributed to avoiding unnecessary surgery. In two other patients,
CT was equivocal for distant metastases (one retroperitoneal
nodal and one omental) but PET was negative, leading to surgical
exploration and successful resection.
Overall, 5 patients benefitted from the additive information
from PET scanning, and in a further 12 patients there was prob-
ably a benefit by confirming suspicious findings on CT. Of the
15 patients who avoided surgery based on PET avidity alone or in
concordance with CT results, 8 had subsequent radiological pro-
gression of disease, 1 had metastatic disease confirmed on biopsy,
and 6 patients were lost to follow-up.
When patients with definitively helpful PET and confirmatory
PET were analysed together, PET was found to be more useful in
patients with nodal disease seen on CT [38% versus 8% if no
nodal disease, odds ratio (OR) 7.1, P = 0.0004). A higher propor-
tion of patients without a prior cholecystectomy also had their
management changed by PET compared with post-
cholecystectomy patients (31% versus 13%, OR 3.1, P = 0.035).
The T classification of primary cancer did not influence the utility
of PET (24% for T1/T2 versus 17% for T3/T4, OR 1.5, P = 0.56).
The influence of these factors on the utility of PET is summarized
in Fig. 2. There was a non-significant trend towards increased
utility of PET when the CT or MRI was done outside (6/12 versus
11/71, OR 3.2, P = 0.08).
In three patients, PET detected three unrelated findings not
seen on CT, including one secondary malignancy and two false-
positive lesions. One patient had a PET-avid cancer within a polyp
in the sigmoid colon which was resected colonoscopically and
confirmed to be malignant. While PET correctly identified this
second malignancy, it however missed the liver metastases and T4
disease invading multiple organs and failed to prevent a non-
therapeutic laparotomy. The second patient had PET avid
mediastinal lymph nodes which led to a mediastinoscopy and
biopsy. Results showed benign disease only. PET also missed the
liver and peritoneal metastases in this patient. The third patient
had PET avid lung nodules which led to a lung resection. Histol-
ogy showed bronchiolitis obliterans organizing pneumonitis. The
gallbladder cancer was successfully resected. Therefore in these
three patients PET resulted in invasive procedures that ultimately
did not benefit the patient. PET did not help avoid surgery in these
cases.
Table 1 Patient demographics, clinical and pathological
characteristics
Total patients 100
Age years, median (interquartile range) 67 (60–74)
Male gender, n 44











Unresectable disease found at surgery, n
Peritoneal metastases 13
Distant nodal metastases 9
Liver metastases 8
Locally advanced disease 7
aPathological T classification if histology available. Clinical classification
if no histology available.
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Table 2 Yield of positron emission tomography (PET) (positive or suspicious for unresectable disease) by T classification
T classification Gallbladder resected
(incidental GBC)
% Yield Gallbladder not resected % Yield Total % Yield
T1 0/5 0 0/1 0 0/6 0
T2 5/17 29 2/2 100 7/19 37
T3 13/37 35 14/27 52 27/64 42
T4 4/5 80 1/6 17 5/11 45
All 22/64 34 17/36 47 39/100 39
GBC, gallbladder cancer.
Figure 1 Flow diagram showing the utility of positron emission tomography (PET). In 73 patients computed tomography (CT) and PET were
completely concordant and PET provided no additional information. In 27 patients CT and PET were not completely concordant and in
17 patients PET provided addition information that influenced management
1026 HPB
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Of the 27 patients who proceeded to the operating room but
were not resected, 6 had a laparoscopy which found unresectable
disease thus avoiding a non-therapeutic laparotomy, 6 had a lapa-
roscopy but unresectable disease was only found after conversion
to a laparotomy, and 15 patients proceeded directly to a
laparotomy.
The presence or absence of metastatic disease was able to be
determined via surgical exploration +/- biopsies in 64 patients. A
further 23 patients who were not explored had adequate follow-up
imaging to detect disease progression. Thirteen patients were lost
to follow-up and therefore the accuracy of their PET results could
not be confirmed. The sensitivity and specificity of PET for meta-
static disease (including regional and distant lymph nodes) were
57% and 94%, respectively, with a PPV of 94% and NPV of 58%.
When individual sites of metastases were considered, the PPV was
highest for peritoneum, followed by the liver, lymph nodes and
lung (100%, 93%, 91% and 67%, respectively). The NPV was
highest for the lung, followed by the liver, lymph nodes and peri-
toneum (99%, 93%, 88% and 84%, respectively). Twenty-three
patients had false-negative PET, including 13 with peritoneal
disease, 6 with retroperitoneal nodal disease and 4 with liver
metastases. These results are summarized in Table 3.
Discussion
Positron emission tomography has been successfully used as an
adjunct to standard cross-sectional imaging such as CT and MRI
for staging of a number of malignancies. In colorectal liver metas-
tasis, one meta-analysis found that PET changed management in
31.6% of patients.19 Other studies showed a similar influence on
management in 38.2% of oesophageal and oesophagogastric
cancers,20 30.9% of head and neck cancers21 and 49% of
melanoma.22
The sensitivity of PET in distinguishing a benign from a malig-
nant gallbladder mass has been reported as 75–80%, and specific-
ity of 82–88%.13–15 The sensitivity of PET for detecting
extrahepatic disease seems to be somewhat poorer, ranging from
56%15 to 100%.16,23 Two studies that compared CT with PET have
shown comparable sensitivity for the primary tumour and
regional disease, but PET appears to be superior in detecting
distant metastases.12,16 However, these studies have the same limi-
tations common to many studies involving PET and gallbladder
cancer, namely a small number of patients and combining gall-
bladder cancer with cholangiocarcinoma in their analyses. Our
study here shows a somewhat lower sensitivity at 57% for detect-
ing metastases. This is likely to be influenced by the high false-
negative rate for peritoneal disease (16%). Small tumour volume
(<1 cm) peritoneal disease may be difficult to diagnose on PET
pre-operatively, as shown in some studies of gastric24 and ovarian
cancer,25 which are similar to gallbladder cancer in their propen-
sity for transperitoneal spread. In recent years, combined or fused
PET/CT has become more common and likely lead to improve-
ment in diagnostic accuracy.26
A study by Petrowsky et al.16 showed that PET changed man-
agement in 8 of 48 (17%) patients with biliary tract cancer, includ-
ing 16 patients with GBC. Butte et al.11 reported their series of 32
patients with incidental gallbladder cancer after a cholecystectomy
and found that PET changed management in 25% owing to







Figure 2 The utility of positron emission tomography (PET) to
provide additional information for patients with (a) no prior cholecys-
tectomy compared with prior cholecystectomy, (b) early T classifi-
cation compared with advanced T classification, and (c) nodal
disease seen on computed tomography (CT) compared with no
nodal disease
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previously reported that PET changedmanagement in 7/31 (23%)
of pre-operative GBC patients.18 These seven patients had meta-
static disease seen on PET that was not seen on CT. In comparison,
in the present study, only two patients had distant metastatic
disease that was completely missed by CT. It should be noted that
our current study included some patients reported in the earlier
study. This difference may be attributed to improving CT and
MRI technology and thus increasing accuracy of standard cross-
sectional imaging. Furthermore, the definition of metastatic
disease differs between the two studies. Corvera et al. included
some patients with regional nodal disease in their unresectable
metastatic group, whereas many surgeons now consider regional
nodal disease resectable, albeit with a poorer prognosis.
We found here that PET was more useful in patients without a
prior cholecystectomy compared with patients who already had
their primary resected. This may be as a result of referral bias, as
patients referred for definitive management after incidental diag-
nosis of GBC would have passed the test of surgical exploration
during their initial cholecystectomy, therefore were less likely to
have metastatic disease of sufficient volume to be visible on PET.
Another important consideration is that PET in the post-
operative setting is difficult to interpret given the inflammatory or
hypermetabolic effects associated with wound healing.
We hypothesized that patients with higher T classifications (T3/
T4) may benefit from PET more than patients with lower T clas-
sifications (T1/T2). Somewhat unexpectedly the results showed
no statistical significance. In contrast, the yield of PET (chance of
positivity) for unresectable disease increased with T classification.
No patient with T1 primary had a positive PET. Patients with T2
and T3 disease had a 35% yield, whereas patients with T4 disease
had a 45% yield. Therefore routine use of PET scans in T1 disease
without other suspicious lesions is probably not cost effective.
However, an increasing yield with more advanced T classifications
did not translate to an equivalent increase in benefit to patients.
This may be because patients with T3/T4 disease were more likely
to have peritoneal disease or small liver metastases, both of which
are often missed by PET. Therefore for higher T classifications,
even although the rate of true positives for PET increased, so did
the false negatives.
Historically, gallbladder cancer has traditionally been treated
with nihilism. As a result of a perceived poor prognosis, surgery
for T3 and T4 disease had been controversial. A survey-based
study by Cubertafond et al. involving 724 surgically treated
patients in Europe and Asia in the 1980s showed that patients with
carcinoma in situ had good outcomes, ones with T1 and T2
disease did poorly, and ones with T3 and T4 cancers had a median
survival of only 3–6 months and no survivors beyond 3 years.8
However modern surgery, where the importance of a liver resec-
tion and regional lymphadenectomy is recognized, has resulted in
improved survival in selected patients. D’Angelica et al. (2009)
reported their series of 104 patients after a resection, where
patients with T3 and T4 disease had a median survival of 24
months and 5-year disease-specific survival of 25%.7 Therefore
even although a long-term cure may not be possible in these
patients, many surgeons will now advocate a radical resection if
technically resectable.
The resectability of patients with nodal disease is also contro-
versial. In the study by D’Angelica et al. nodal positivity was asso-
ciated with a much worse prognosis, with a median survival of 18
months and 5 years disease-specific survival of 17%, compared
with 65 months and 51%, respectively, for node-negative
patients.7 Several studies have shown that regional nodal involve-
ment, although still a poor prognostic factor, represents a better
group than distant nodal disease.13,27,28 In the 7th edition of AJCC
Cancer StagingManual (2009), nodal disease is now separated into
N1 (regional nodes including portal and hepatoduodenal) and N2
(distant nodes including periaortic, pericaval, superior mesenteric
artery and celiac), with the latter upstaging the patient from stage
III in AJCC 6th edition to stage IVA.29 On the contrary, there have
been some Japanese studies that showed the number of positive
nodes but not the location of the nodes independently predicted
survival.30,31 There is probably no benefit in resecting extensive
nodal disease, but these patients may benefit from a neoadjuvant
approach and pre-operative PET may help identify these patients.
Overall the use of PET was definitively helpful in 5%, confirma-
tory in 12% and harmful in 3% of our patients. Our data suggests
that with modern high-quality cross-sectional imaging, it is
uncommon for PET findings to be the sole determinant of
resectability. However, we found that PET was more useful in a
confirmatory role, particularly in patients with equivocal N2
disease, where PET positivity would be a contraindication to
resection. The risk of PET doing harm owing to false positivity by






Patients with positive PET, n 33 5 21 15 3
Patients with true metastases, n 53 18 27 19 3
Sensitivity, % 57 28 70 74 67
Specificity, % 94 100 97 99 99
Positive Predictive Value, % 94 100 91 93 67
Negative Predictive Value, % 58 84 88 93 99
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PET must also be considered. Although false-positive PET scans
that prevent a patient from having curative surgery are probably
rare, false-positives that result in unnecessary additional pro-
cedures occurs occasionally (3% in this study).
In spite of the use of CT/MRI and PET, 27 patients still under-
went non-therapeutic surgery. Laparoscopy spared six of those
patients from a laparotomy. A study byWeber et al. (2002) involv-
ing 44 patients with gallbladder cancer who had a staging lapa-
roscopy showed a yield of 48% and an accuracy of 58% in
detecting unresectable disease.32 More recently, a study by Agarwal
et al. involving patients with 409 primary gallbladder cancer
showed a yield of 23.2%, overall accuracy of 55.9% and for detect-
ing surface liver and peritoneal metastases a accuracy of 94.1%.33
These results suggest that there should be a low threshold for
laparoscopy in GBC. These studies also showed that the yield of
laparoscopy increased with higher T classifications, but not the
accuracy, owing to increased false negatives with higher T classi-
fications, a finding analogous with our current results with a
different diagnostic modality.
The retrospective nature of this study poses some limitations on
our results. Whether the addition of PET changed management
was retrospectively and subjectively assessed and the multitude of
factors that influenced the clinician’s decision at the time may not
be fully realized. As a group our selection criteria for surgery has
been well defined and consistent, hence the decision-making
process should be fairly reproducible. Nonetheless, for patients
where PET appeared to be confirmatory for equivocal metastatic
lesions, it is difficult to be certain if PET truly changed manage-
ment. Another limitation is that the PET scans were not reviewed
by a blinded radiologist. As the PET scans were often performed
after the CT scans were reported, the interpretation of the PET
may be biased. Furthermore, the true accuracy of the imaging
studies cannot be confirmed in all patients, as 36/100 patients did
not undergo surgical exploration. In 23 patients with adequate
imaging follow-up, progression of disease was used as indirect
evidence for confirmation of initial imaging findings. Thirteen
patients were lost to follow-up hence the accuracy of their imaging
is unknown.
Finally, the utility of PET over conventional imaging in any
study must be interpreted with the quality of the standard cross-
sectional imaging in mind, as apparent usefulness of PET may be
a reflection of poor detection rates with CT/MRI. In this study,
18% of CT/MRI and 6% of PET scans were performed at another
institution, which may introduce some heterogeneity in the inter-
pretation and reporting of metastatic lesions. In our experience,
the quality of CT or MRI scans done outside tertiary oncology
referral centres are often suboptimal, and this may lead to an
overestimation of the the utility of PET. However, we found no
statistically significant difference in the utility of PET between
patients whose CT/MRI scans were done at MSKCC or at an
outside hospital. The role of PET may diminish as the quality of
CT and MRI continue to improve, enabling small liver, lung, or
peritoneal metastases to be detected. However, the determination
of metastatic involvement of lymph nodes is still problematic on
CT andMRI. There are little data specifically examining the size of
regional lymph nodes and their correlation with histological
nodal positivity in gallbladder cancer. One study found that in
patients with biliary cancer, regional nodes with a short-axis
diameter >16 mm had a PPV of only 56% for metastatic involve-
ment.34 PET may help overcome this limitation, especially in
patients with enlarged N2 nodes in the celiac, retropancreatic,
aortocaval and para-aortic regions, where PET avidity will likely
render them unresectable. Another potential area where PET may
become more useful in the future is in the setting of neoadjuvant
chemotherapy, which has not been widely practiced for biliary
cancers owing to the lack of evidence for its efficacy. However,
with improving systemic agents, the assessment of response may
become more important in selecting patients for subsequent
resection with curative intent.
Conclusion
PET is highly specific for metastatic gallbladder cancer but not
sensitive, particularly for small volume peritoneal disease. The
addition of PET to standard staging CT may be helpful in 17% of
patients to improve classification of equivocal lesions by CT or
MRI and identify distant metastatic disease, but may cause harm
in 3% of patients. FDG-PET appears to be complimentary rather
than definitive in many patients with GBC, and its role is limited
in patients with negative CT/MRI and T1 disease. While the
routine use of PET in GBC is probably not cost effective, we
believe that PET should be used when there are suspicious find-
ings on CT/MRI, such as large tumours, questionable nodes or
peritoneal infiltration.
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